Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $320

Revolution Medicines

Revolution Medicines

RVMD

0.00

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ: RVMD) with a Outperform and raises the price target from $230 to $320.